PYC Therapeutics (ASX:PYC) received all regulatory approvals to start human trials of its drug candidate for polycystic kidney disease, the company said in a Monday Australian bourse filing.
Polycystic kidney disease is a life-changing disease where multiple cysts form throughout a patient's kidney that increase in size over time.
Dosing of patients in the single ascending dose study is expected to be completed in about 12 months with a budgeted cost of AU$10 million, per the filing. The primary endpoint is treatment-emergent adverse events and treatment-emergent serious adverse events.
The initial human safety and efficacy data are anticipated within the year, the filing added.
Company shares were up nearly 3% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.